Bioventix (LSE:BVXP), the Surrey-based developer of antibodies used in clinical diagnostics, published its results for the year to 30 June 2026 on 26 October, followed by its Annual Report and notice of Annual General Meeting on 6 November.

What the company does

Bioventix creates and supplies sheep monoclonal antibodies, which it licenses to large diagnostics companies for use in blood tests run on automated analysers in hospitals and laboratories. The company earns most of its income from royalties linked to its partners' sales of those tests. Its products have historically been used in assays including vitamin D, and it has been developing antibodies for neurological conditions, including Tau proteins associated with Alzheimer's disease.

Latest developments

In its interim results for the six months to 31 December 2025, published in March 2026, Bioventix reported Revenue of £6.16 million, down from £6.73 million, and pre-tax profit of £4.85 million, down from £5.05 million. Tau and neurology-related royalties rose about fivefold to roughly £150,000, which the company attributed to its antibodies being used in research-use-only Alzheimer's assays. It said trading was in line with full-year expectations. A director dealing was disclosed in June.

Financial and Dividend picture

Bioventix is known for paying out most of its earnings. It held the Interim Dividend at 70p in March, and the reported 150p full-year figure matches the prior year. Closing cash at the half-year stood at £5.3 million. The shares traded between 1,320p in March 2026 and about 2,219p in November 2025 over the past year.

Sector and index context

Bioventix (LSE:BVXP) is one of the few consistently profitable, cash-generative healthcare companies among smaller AIM stocks, and it has been well regarded by income-focused investors. Diagnostics markets have been mixed: some established tests face pricing pressure and competition, while interest in blood-based tests for Alzheimer's disease has grown as new treatments emerge. Within the FTSE AIM All Share Index, it sits among the mid-sized healthcare constituents.

Key risks

The company relies on a small number of large diagnostics customers and on Royalty streams that can decline as products mature or face competition, as the vitamin D trend suggests. Neurology royalties remain small and depend on partners advancing tests towards clinical use. Exchange rates also affect revenue, as royalties are paid in foreign currencies. Because the company distributes most of its profits, any sustained fall in royalty income would feed directly into the dividend, which is a central part of its appeal to many shareholders. The recent rally also means the valuation leaves less room for disappointment.

What to watch next

Shareholders will be watching the annual general meeting for any trading commentary, the pace of growth in Tau-related royalties and whether new antibodies reach commercial use. The interim results, usually published in the spring, will show whether revenue has stabilised and whether the dividend policy can be maintained at current levels.